Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG CLGX818AUS03

Title
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFC600 Mutated Tumors
Principal Investigator
Melissa Johnson
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG CLGX818AUS03
Purpose
Researchers want to know if LGX818 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a BRAFV600 activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
Overview
LGX818 is a drug that is being developed for the potential treatment of different tumor types and/or blood malignancies. LGX818 is a new type of drug that works by slowing down an important pathway inside the cell involved in the development of certain types of cancers. BRAF is a signaling protein in a cell growth sequence called “the MAPK pathway.” Mutations in the BRAF gene are found to various degrees in many cancers including blood malignancies, leading to or accelerating their growth. LCX818 works by slowing down the activity of mutated BRAF (“BRAFV600”). So far, at least 92 people have received one or more doses of LGX818, either alone or in combination with other anti-cancer drugs.
Eligibility
Some of the eligibility criteria include:
  • Participants must be at least 18 years of age.
  • Participants must have a confirmed diagnosis of a select solid tumor (except for colorectal cancer or melanoma) or hematologic malignancy.
  • Participants must need treatment for their cancer because it is getting worse.
  • Participants must have a tumor with a mutation in BRAFV600. This is determined by genetic testing.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
In this study, a complete dosing cycle is 28 days. In each cycle, participants will take LGX818 by mouth once a day, at approximately the same time (starting at Day 1 of Cycle 1). Participants may continue to receive study drug unless they and/or the study doctor decide to stop the study drug dosing.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Melissa Johnson

last updated: 21-Oct-14 01:21 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.